Dr. Kraft is a Stanford and Harvard trained physician scientist and innovator in the field of stem cells and regenerative medicine with over 20 years of clinical and biomedical research experience. He is an NIH funded faculty member with the Stanford Institute for Stem Cell Biology and Regenerative Medicine and is on clinical faculty with the UCSF pediatric bone marrow transplantation service.

Dr. Kraft has extensive research experience focused on stem cell biology and immunology. In early research experience at the National Institutes of Health, he was the first to propose and demonstrate proof of concept for a monoclonal antibody based therapy for allergic disease, an approach later translated to a novel humanized antibody therapeutic by Genentech (Xolair). Research at Brown University, and later at Harvard medical school focused on HIV and its interaction with the immune system. As a Howard Hughes research fellow at Stanford he discovered a novel population of developing human T-cells. Dr. Kraft also was a research fellow with SyStemix, a company which pioneered purified hematopoietic stem cell based therapies. His research focus after returning to Stanford has been on stem cell derived immunotherapy, working to understand and engineer the stem cell niche, and novel antibody based conditioning regimens for stem cell transplantation. He has multiple peer-reviewed publications, book chapters, and lectured extensively on stem cell biology and regenerative medicine.

Daniel is a member of, and has made presentations at the annual meetings of, the International Society of Stem Cell Research (ISSCR), American Society of Hematology (ASH) and the American Society of Bone Marrow Transplantation (ASBMT). He has additional research and clinical expertise in aerospace medicine (served as flight surgeon with an F-15 squadron in the Massachusetts Air National Guard) and has published his research with NASA, with whom he was recently a finalist for astronaut selection.

In 2003, Dr. Kraft founded and served as CEO for StemCor Systems, a venture and corporate funded clinical stage medical device company developing tools to enable adult stem cell based regenerative therapies. The original ideas and designs for these novel devices were based upon inventions and intellectual property that Dr. Kraft developed.  At StemCor, Dr. Kraft also worked on the preclinical and clinical trials, as well as helped drive the Company's successful FDA 510(k) approval.  He now serves on the Board, chairs the Company's Advisory Board and is the consulting Chief Medical Officer. In 1996 Dr. Kraft founded, developed, and operated an internet based marketplace for medical professionals. This business was acquired by Netivation, Inc. in 1999 in conjunction with its IPO. Dr. Kraft has also served as an advisor to multiple biotechnology companies and private equity investment firms.

Dr. Kraft obtained a degree in Biochemistry cum laude from Brown University, and went on to complete medical school at Stanford University, where he was a Howard Hughes Research Fellow and graduated with honors in research. After medical school Dr. Kraft completed the four year Harvard Combined Residency in Internal Medicine and Pediatrics at the Massachusetts General Hospital and Boston Children's Hospital. While a resident he conducted research with the Harvard Transplantation Biology Research Center. Dr. Kraft then returned to Stanford for fellowship training in Hematology/Oncology and an additional fellowship in Bone Marrow and Hematopoietic Stem Cell Transplantation and a postdoctoral research fellowship in the stem cell laboratory of Irv Weissman. He is board certified in Internal Medicine, Pediatrics and BE in Hematology/Oncology.